Don't miss our weekly PhD newsletter | Sign up now Don't miss our weekly PhD newsletter | Sign up now

  Do nanomedicines have the potential to combat antimicrobial resistance?


   School of Applied Sciences

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
  Dr N Wheelhouse, Dr Samantha Donnellan, Prof S Dancer  No more applications being accepted  Funded PhD Project (UK Students Only)

About the Project

The increase in prevalence of clinical infections caused by Antimicrobial resistant (AMR) organisms is of great concern. Urgent action is needed to prevent the development of a post-antibiotic era whereby common infections have strikingly high mortality rates1,2. Novel and/or repurposed drugs to treat infections are urgently required. The repurposing of licenced drugs is an approach that provides the quickest route to clinical use providing they are shown to be both safe and effective.

Nano-formulations of antibiotics hold great promise to improve human medicine including the possibility of lowering the drug dose administered, causing fewer side effects and reducing the risk of AMR3,4. Traditionally toxicology and efficacy studies have been performed in mammalian species. However, there are a range of ethical and practical issues with the use of mammals particularly in early stage studies. The Galleria mellonella (wax moth larvae) offers a well characterised alternative invertebrate model for drug screening and virulence testing5 .

The aim of this project is to develop and screen the efficacy of novel nano-medicines on a range of clinically relevant bacterial strains within the G. mellonella model. This is an exciting and innovative collaborative project between Edinburgh Napier University and The University of Liverpool and The Moredun Research Institute. You will join an active postgraduate research group and have the opportunity to engage with a vibrant postgraduate research community. You will have opportunities to present at national/international conferences as well as taking part in a full Edinburgh Napier University run training programme.

Academic qualifications

A first degree (at least a 2.1) ideally in Microbiology, Biomedical Science or related discipline with a good fundamental knowledge of biology.

English language requirement

IELTS score must be at least 6.5 (with not less than 6.0 in each of the four components). Other, equivalent qualifications will be accepted. Full details of the University’s policy are available online.

Essential attributes:

• Experience of fundamental analytical skills including statistics and data analysis

• Competent in basic laboratory skills and aseptic technique

• Knowledge of microbiology and/ or biomedical science

• Good written and oral communication skills

• Strong motivation, with evidence of independent research skills relevant to the project

• Good time management

Desirable attributes:

Microbiological culture, antimicrobial susceptibility testing and environmental sampling, nano-drug development/or drug screening experience

When applying (PhD APPLIED SCIENCES full-time), please quote the application reference SAS0168 on your form.

Biological Sciences (4) Medicine (26)

Funding Notes

This project is fully funded at the standard Edinburgh Napier studentship rates. Funding will include payment of the Home full-time fees for three academic years, plus 36 monthly stipend payments at the prevailing rate set by the UK Research Councils (2021/22 Stipend rate is £15,609 per year). Students must be eligible for Home fee status in order to apply for this project. Interviews will take place late early February 2022. Students must be able to commence their studies in March 2022.

References

1. WHO. Antimicrobial resistance: global report on surveillance 2014. https://www.who.int/drugresistance/documents/surveillancereport/en/(2014).
2. WHO. Antibiotic Resistance. Fact Sheets https://www.who.int/newsroom/fact-sheets/detail/antibiotic-resistance (2020).
3. Mcdonald, T. O. et al. Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro-In Vivo Correlation. Adv. Healthc. Mater. 3, 400–411 (2014).
4. Donnellan, S. et al. A rapid screening assay for identifying mycobacteria targeted nanoparticle antibiotics. Nanotoxicology 10, 761–769 (2015).
5. Sheehan, G. et al. Utilization of Galleria mellonella larvae to characterize the development of Staphylococcus aureas infection. Microbiology 165, 863-875 (2019